Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 110,622

Document Document Title
WO/2015/140130A1
The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the d...  
WO/2015/140081A1
A compound of the formula (I) or a tautomeric isoform thereof wherein R1 is selected from the group consisting of halogen, nitro, lower alkyl sulfonyl, cyano, trifluromethyl lower alkyl, lower alkoxy, lower alkoxycarbonyl, carboxy, lower...  
WO/2015/139847A1
The present invention relates to a composition for use in an orally, or rectally, transdermally or nasally administered medicament, characterized in that it includes: (b) at least one compound of Formula (I) and (b) at least one permeati...  
WO/2015/139386A1
The present invention relates to Canagliflozin monohydrate and crystal form thereof. Compared with the prior art, the Canagliflozin monohydrate and crystal form has higher stability in water or an aqueous system, is more suitable for a w...  
WO/2015/142500A3
This invention relates to compositions containing combinations of a balanced PC composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of ...  
WO/2015/139638A8
Provided herein are the acid addition salts of the compound named (2S, 4S) -1- [2- [ [5-hydroxy-2-methyl-3, 3a, 4, 5, 6, 6a-hexahydro-1H-pentalen-2-yl] amino] acetyl] -4 -fluoro-pyrrolidine-2-carbonitrile, preparation methods and pharmac...  
WO/2015/143379A1
Several embodiments disclosed herein relate to methods for calculating a dosing regimen that is tailored specifically to the genetic and metabolic profile of a particular patient. In some embodiments, the dosing regimen is related to adm...  
WO/2015/140559A1
This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds...  
WO/2015/140736A1
Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoi...  
WO/2015/140799A1
An active agent capable of reducing quinone reductase 2 activity, for use in improvement of cognition in a subject is provided. Such an active agent may be a nucleic acid molecule that reduces the gene expression level of quinone reducta...  
WO/2015/142714A1
The adaptor associated kinase 1 (AAK1) inhibitor 3-methyloxetan-3-yl-4-(3-(2-methoxypyridin-3-yl)pyrazolo[1,5 -a]pyrimidin-5-yl)piperazine-1-carboxylate: and pharmaceutically acceptable salts and solid forms thereof are disclosed. Compos...  
WO/2015/139638A1
Provided herein are the acid addition salts of the compound named (2S, 4S) -1- [2- [ [5-hydroxy-2-methyl-3, 3a, 4, 5, 6, 6a-hexahydro-1H-pentalen-2-yl] amino] acetyl] -4 -fluoro-pyrrolidine-2-carbonitrile, preparation methods and pharmac...  
WO/2015/142061A1
The present invention relates to a composition for treating inflammatory brain disease comprising stem-cell-derived exosome as an active ingredient. The stem-cell-derived exosome according to the present invention can advantageously be u...  
WO/2015/138917A1
Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e....  
WO/2015/136027A1
The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of...  
WO/2015/137499A3
 A hydrogen molecule-supplying exterior body (1) for producing a hydrogen-containing biological application solution, said hydrogen molecule-supplying exterior body (1) being provided with a water vapor-permeable container (12) in whic...  
WO/2015/135947A1
The present invention relates to piperazine phenothiazine derivatives useful as therapeutic agents for treating spasticity, particularly following an ischemia or traumatic injury, or compression syndrome. The invention further relates to...  
WO/2015/137419A1
[Problem] The purpose of the present invention is to activate abnormal mesenchymal stem cells that have experienced a loss or reduction in therapeutic efficacy, or that have a disease-exacerbating effect, and restore the cells to a condi...  
WO/2015/139056A1
Provided are combinations of homeopathic remedies to be used by persons inclined to addictive situations as well as methods for delivery of such preparations. The combination includes the nine remedies of Argentum Nitricum, Arsenicum Alb...  
WO/2015/136091A1
The present invention relates to tricyclic hexahydrodiazepinoquino lines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especia...  
WO/2015/136247A1
The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called "DREADD" receptor being characterised by (i) a decreased respons...  
WO/2015/136253A1
The disclosure provides extended release pharmaceutical formulations comprising an opioid,particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The ...  
WO/2015/136003A3
Disclosed is a pharmaceutical composition comprising i) a dopamine agonist and ii) a L-DOPA derivative in combination in form of a liquid preparation. The pharmaceutical composition is used for the treatment of Parkinson's disease, restl...  
WO/2015/137441A1
Provided is an anti-myristoylated protein antibody or antigen-binding fragment thereof, characterized by having a light-chain variable domain consisting of CDR-L1 comprising the amino acid sequence shown by Sequence No. 1, CDR-L2 compris...  
WO/2015/136515A1
Compositions, methods and devices for administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods can be utilized for treating conditions such as neuropsychiatric sympto...  
WO/2015/136541A3
A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the a...  
WO/2015/138689A1
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegen...  
WO/2015/137887A1
The present invention relates to fused pyrimidine-based hydroxamate compounds of formula (I), comprising a hydroxamate group, that are inhibitors of histone deacetylase (HDAC) and kinases. More particularly, the present invention relates...  
WO/2015/138496A1
Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazin...  
WO/2015/138208A1
The present invention provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof.  
WO/2015/136255A1
The invention relates to the use of agents for the inhibition of caspase-2 and caspase-6 in the protection of central and peripheral neurons. In particular, the invention comprises an inhibitor of caspase-2 for use in the treatment of a ...  
WO/2015/136463A1
The invention is directed to substituted pyrrolidinone derivatives. Specifically, the invention is directed to compounds according to Formula X: wherein R41, R42, R43, R44, R45, R46, and R47 are defined herein. The compounds of the inven...  
WO/2015/137499A2
 A hydrogen molecule-supplying exterior body (1) for producing a hydrogen-containing biological application solution, said hydrogen molecule-supplying exterior body (1) being provided with a water vapor-permeable container (12) in whic...  
WO/2015/136543A1
Compositions, methods and devices for administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods can be utilized for treating conditions such as neuropsychiatric sympto...  
WO/2015/137357A1
 The present invention provides a composition containing a sophorolipid, physiologically active substance and oil and fat, said composition being capable of improving the bioavailability of the physiologically active substance when ora...  
WO/2015/135474A1
Disclosed are a pentacyclic triterpene compound represented by general formula (I) and pharmaceutical compositions containing the compound. Also disclosed is use of the compound in preparation of a PS1/BACE1 interaction inhibitor, and us...  
WO/2015/136947A1
The present invention relates to azaspiro derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in th...  
WO/2015/136090A1
The present invention relates to tricyclic hexahydrodiazepinoquino lines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially ago...  
WO/2015/132800A1
The present invention relates to a composition for relieving one or more of the conditions of pain, stress and insomnia comprising Brassica compestris, Bees wax and Dryobalanops camphora. The present invention also provides a formulation...  
WO/2015/132141A1
The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pre...  
WO/2015/131856A1
Provided are heterocyclic compounds represented by formula (I), stereoisomers or pharmaceutically acceptable salts of said compounds, a pharmaceutical composition of said compounds, and an application of said compounds in the preparation...  
WO/2015/132608A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein R1 and R2 arc as defined in the specification, for use in the prevention or treatment of an ataxic disorder.  
WO/2015/134545A2  
WO/2015/133627A1
 The present invention provides an agent to prevent or improve debility, the agent containing as an active ingredient isoleucine and threonine, and an agent to prevent or improve debility, the agent further containing as an active ingr...  
WO/2015/133329A1
 Provided is a patch preparation having improved adhesion to an adherend so as to be able to continuously administer a drug, particularly a drug having systemic action, in a consistent fashion for an extended period. The patch preparat...  
WO/2015/131788A1
Provided are methods of producing a neuronal phenotype in a glial cell or somatic non-neuronal cell. The methods comprise contacting the glial cell or the somatic non-neuronal cell with a composition including small molecules. Also provi...  
WO/2015/131797A1
Provided are a method for inducing the transdifferentiation of somatic cells into neural stem cells and application for same. Using a combination of a histone deacetylase (HDAC) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, an...  
WO/2015/132800A4
The present invention relates to a composition for relieving one or more of the conditions of pain, stress and insomnia comprising Brassica compestris, Bees wax and Dryobalanops camphora. The present invention also provides a formulation...  
WO/2015/134133A1
The present invention is directed to kits and methods for the treatment of a patient suffering from post-traumatic stress disorder (PTSD) and/or hot flashes by an administration of a mixture produced by a combination of a long acting loc...  
WO/2015/133771A1
The present invention relates to a novel biomarker for neuroglioma and a use thereof, and more specifically, to a composition for diagnosing neuroglioma comprising a nucleic acid molecule encoding a stanniocalcin protein, a complementary...  

Matches 701 - 750 out of 110,622